KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) Debt to Equity (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Debt to Equity for 8 consecutive years, with -$0.32 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Debt to Equity rose 55.8% year-over-year to -$0.32, compared with a TTM value of -$0.32 through Dec 2025, up 55.8%, and an annual FY2025 reading of -$0.32, up 55.8% over the prior year.
  • Debt to Equity was -$0.32 for Q4 2025 at Biocryst Pharmaceuticals, up from -$0.66 in the prior quarter.
  • Across five years, Debt to Equity topped out at -$0.32 in Q4 2025 and bottomed at -$0.77 in Q1 2025.
  • Average Debt to Equity over 3 years is -$0.69, with a median of -$0.72 recorded in 2024.
  • Peak annual rise in Debt to Equity hit 55.8% in 2025, while the deepest fall reached 10.16% in 2025.
  • Year by year, Debt to Equity stood at -$0.72 in 2023, then dropped by 1.79% to -$0.73 in 2024, then surged by 55.8% to -$0.32 in 2025.
  • Business Quant data shows Debt to Equity for BCRX at -$0.32 in Q4 2025, -$0.66 in Q2 2025, and -$0.77 in Q1 2025.